Lu-177 has been developed for the treatment of patients with peptide receptor radionuclide
therapy (PRRT). A second generation pure no-carrier-added Lu-177 has a high specific …

Peptide receptor radionuclide therapy (PRRT) is an established treatment for grade 1 and 2
gastroenteropancreatic neuroendocrine tumors with an increased uptake on somatostatin …

This ENETS guidance paper for well‐differentiated nonfunctioning pancreatic
neuroendocrine tumours (NF‐Pan‐NET) has been developed by a multidisciplinary working …

Neuroendocrine neoplasms (NENs) arise from the diffuse neuroendocrine cell system and
may occur at many different disease sites. Most frequently, these neoplasms occur in the …

This ENETS guidance paper, developed by a multidisciplinary working group, provides up‐
to‐date and practical advice on the diagnosis and management of digestive neuroendocrine …

This article is the result of the North American Neuroendocrine Tumor Society consensus
conference on the medical management of pancreatic neuroendocrine tumors from July 19 …

High-grade neuroendocrine neoplasms are a rare disease entity and account for
approximately 10% of all neuroendocrine neoplasms. Because of their rarity, there is an …

High-grade gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are classified
according to morphology as well-differentiated neuroendocrine tumours (NETs) G3 or poorly …

Both the incidence and prevalence of well‐differentiated neuroendocrine tumours from the
small intestine (Si‐NET) are gradually increasing. Most patients have non‐functioning …

Continuous progress in the diagnostics and treatment of neuroendocrine neoplasms
(NENs), the emerging results of new clinical trials, and the new guidelines issued by medical …